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The OMERACT Safety Working Group objective was to identify harm domains from existing outcome 3 
measurements in rheumatology. 4 
Methods: 5 
Systematically searching the MEDLINE database January 24, 2017, we identified full-text articles that could 6 
be used for harm outcomes in rheumatology. Domains/items from the identified instruments were described 7 
and the content synthesized to provide a preliminary framework for harm outcomes. 8 
Results: 9 
From 435 possible references, 24 were read in full text, and 9 were included: Seven measurement 10 
instruments were identified. Exploration of domains/items revealed considerable heterogeneity in the 11 
grouping and approach. 12 
Conclusion: 13 
The ideal way to assess harm aspects from the patients’ perspective has not yet been ascertained. 14 





Harms provide important context for healthcare practitioners about the benefit-risk ratio of interventions (1). 2 
To improve transparency and credibility in the published results from randomized trials, the reporting of 3 
harms associated with an intervention needs to be explicit regarding what is patient-important which may be 4 
different from that reported by clinicians submitting adverse event reports (2). The ’Consolidated Standards 5 
of Reporting Trials’ (CONSORT) group has provided recommendations on the appropriate reporting of 6 
harms in randomized controlled trials (RCTs) (3). However, systematic reviews conclude that adherence to 7 
these CONSORT Harm recommendations is suboptimal in RCTs for (non)pharmacological treatment of 8 
rheumatoid arthritis (RA) and hip or knee osteoarthritis (OA) (4,5) as reported in leading medical journals. 9 
According to Hadi et al, more than half (56%) of the RCTs reported ≤50% of the recommended CONSORT-10 
harm items. While some CONSORT harm items might be more important to consider reporting than others, 11 
there is a need to improve harms reporting in RCTs to allow transparent and balanced assessment of the 12 
benefit-risk ratio in clinical decision making (5). 13 
Following the concerns about inadequate reporting of  harm outcomes in randomized trials (3) 14 
and systematic reviews (1,6), the ‘Outcome Measures in Rheumatology’ (OMERACT) Safety Working 15 
Group is advancing the work to identify additional harm aspects for assessment in rheumatology trials (7,8). 16 
To inform this work, we performed a scoping review of harm aspects, assessed in existing measurement 17 
instruments, using an approach suggested by Macefield (9) and McNair (10). The objective was to identify 18 
harm domains from the patient perspective by examining currently available outcome measurement 19 
instruments. 20 
 21 
METHODS  22 
The protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO, 23 




interest in terms of the volume, nature, and characteristics of the primary research, which is feasible when 1 
the topic has not yet been extensively reviewed or is of a complex or heterogeneous nature (11). The purpose 2 
of a scoping review is to sum up the best available research on a specific question (12). 3 
An electronic search was performed January 24, 2017 using Medline via PubMed to identify 4 
studies describing or evaluating measurement instruments including harm outcomes that could be used in 5 
rheumatology trials. The search strategy included terms for harms, rheumatic disease and outcome measures. 6 
No filters were activated (e.g. no article type, availability, publication date, language restrictions). Additional 7 
references were identified through reference lists of included studies and by consulting experts within 8 
rheumatology (i.e. snowballing). One review author (LK) screened the titles and abstracts of the identified 9 
publications. A second reviewer (RC) screened a random sample of abstracts to check accuracy of inclusion. 10 
Publications were eligible if they described or evaluated instruments including harm outcomes (either 11 
domains or measurements) that could be used in rheumatology trials. Full-text was obtained for all titles that 12 
appeared to be eligible or where there was any uncertainty. Two reviewers (LK and RC) screened the full-13 
texts and excluded publications not in English, and publications reporting results from trials, i.e. studies with 14 
the purpose to evaluate the effects of a treatment. Reasons for exclusion of publications were documented. 15 
Every step of the selection process was documented by a flow chart. Reference manager 12 (Thomson 16 
Reuters, New York, USA) was used to manage references. 17 
Verbatim names for the harm aspects as termed by the instrument developers were extracted 18 
and all Patient-Reported Outcome Measures (PROMs; scales, subscales and single items) were collated in a 19 
list. Using a standardized form, one reviewer (LK) extracted data from each included study. Another 20 
reviewer (RC) verified the data. Extracted data, if available, included: first author, study publication year, 21 
aim of the study, name and abbreviation of outcome measurement instrument, reported harm aspects (i.e. 22 
scales/domains and items), definition of harm aspects, target population. All PROM items assessing adverse 23 
effects were systematically categorized into conceptual health domains according to the issue they addressed. 24 
As suggested by Macefield (9) and applied by McNair (10): (i) we summarize PROMs and (ii) categorize 25 




rheumatology trials. Individual items from all questionnaires were extracted and formed into a long-list 1 
before categorization into health domains by two researchers (LK and RC). 2 
Following this, eight of the authors (LK, MB, DD, VSS, NG, LM, PT, RC) were encouraged 3 
to categorize all items “in any way they found meaningful”, and subsequently to name the categories as they 4 
rationalized based on experience (further details are available from the corresponding author upon request): 5 
Using concept mapping software, the average categorization was estimated through multidimensional scaling 6 
analysis, as an expression of consensus of the distribution of items (13).  7 
 8 
RESULTS 9 
As illustrated in Figure 1, of 435 unique references identified, 24 were read in full text, and of these, 9 were 10 
included (14–22). One reference was excluded due to ‘other language than English’. An overview of the 9 11 
included studies is presented in Table 1. From these, eight unique instruments were identified. Two 12 
instruments (STI and RCTC) were the subject of two studies each, the newest study describing a revision or 13 
update of the original instrument. There were seven individual measurement instruments, and one 14 
methodological proposal referred as the OMERACT 3x3 (19): (i) Stanford Toxicity Index (STI) (14); (ii) 15 
Revised Stanford Toxicity Index (rSTI) (15); (iii) Rheumatology Common Toxicity Criteria 2.0 (RCTC 2.0) 16 
(18); (iv) The Patient Self-Report Adverse Event Instrument and the Investigator Report Adverse Event 17 
instrument (17); (v) The BioSecure questionnaire (20); (vi) Safety of Estrogens in Lupus Erythematosus 18 
National Assessment (SELENA)-SLEDAI flare index (cSFI) (21); (vii) Glucocorticoid Toxicity Index (GTI) 19 
(22). 20 
Five of the seven individual instruments aimed to assess ‘toxicity’, one of these instruments 21 
specifically in relation to treatment with corticosteroids. The content, indicated by subscales of the 22 
instruments, varied despite the common construct of ‘toxicity’. The other instruments aimed to assess 23 




The structure of the instruments varied; one was a PROM (20), the others were 1 
investigator/clinician reported. Altogether there were 205 unique items, or 223 when taking into account the 2 
response options (e.g. the item ‘What was (were) the side effects?’, was accompanied by 37 response 3 
options). Different types of information were retrieved by the items, as shown in Table 2. Most (125) items 4 
or response options each represented a symptom, sign or diagnosis which could be an adverse effect (further 5 
details are available from the corresponding author). 6 
 7 
DISCUSSION 8 
Based on a scoping review, we identified instruments to assess harm aspects in rheumatology trials. ‘Harm 9 
aspects’ is a very broad and complex construct, and this review illustrates that there are many potential 10 
approaches to address it. Harm aspects reported with existing instruments included: ‘Toxicity’, ‘Event 11 
importance’, ‘Benefit and harm’, ‘Self-care safety skills’, and ‘Flare’. These could be categorized as patient 12 
reports, clinician/researcher reports, laboratory results, qualitative descriptions of patients’ experiences and 13 
data from medical records, and only 4 instruments provided a patient perspective. Feasibility around this 14 
review made us perform the systematic search including only one electronic bibliographic database 15 
(Medline), as well as the manual search in reference lists and contact with key opinion leaders in 16 
rheumatology. Thus, a potential limitation to the present manuscript is that we did not include additional 17 
electronic databases. 18 
The current “clinical trial practice” for reporting adverse events is based on the implicit 19 
assumption that an accurate portrait of patients’ subjective experiences can be provided by clinicians’ 20 
documentation alone. Our findings derived from the existing instruments developed for rheumatology (14–21 
18,20–22) at least seem to support the grouping which was previously suggested by US National Cancer 22 
Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events 23 
(PRO-CTCAE) initiative (23). Our work support the idea that there are three broad categories of “harms” 24 




laboratory-based events, (ii) observable/measurable events, and (iii) symptomatic adverse events. Yet, how 1 
the clinician/trialist reports of symptomatic AEs as recorded on case report forms (CRFs) lacks reliability. 2 
There is a risk that clinicians underreport the incidence and severity of symptoms compared to patients’ 3 
direct reports, especially for subjective symptoms, in part because the clinician cannot observe these 4 
symptoms. If a patient-reported outcome measure was available, it could enable direct patients reporting of 5 
their own symptomatic AEs, providing important evidence of patients’ adverse experiences with an 6 
intervention to contribute to shared decision-making. 7 
From this scoping review, we hope to raise awareness about the need for a novel explicit harm 8 
reporting paradigm in rheumatology research, with a focus on patient self-report with the potential to enable 9 
reporting of safety rather than harms. One important issue is how best to collect data on harm and/or safety 10 
outcomes, and whether available measurement instruments are suitable for the purpose. Harm aspects can be 11 
defined and targeted in many ways, reflecting the complexity of the construct. It is clear from this review 12 
that the ideal way to assess harm aspects has not yet been achieved, as well as the language used to cover the 13 
various “domains” is difficult to comprehend for laymen (incl. patients). The OMERACT safety working 14 
group will continue to explore harm aspects, with a specific focus on patients’ perspectives on safety. 15 
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FIGURE LEGENDS 20 
Figure 1   21 
PRISMA = Preferred Reporting Items for Systematic Reviews 22 
